definiens: shall mean, with respect to either Party, any corporation or entity controlled by, controlling or undercommon control with such Party . The terms, or shall mean : ( i ) the director indirect ownership of more than fifty percent ( 50 % ) of the voting securities of any corporation or entity, or(ii ) the power to direct or cause the direction of the management or policies of such corporation or entitythrough the ownership of securities or interests, by contract or otherwise ; 1.2 shall mean this Collaboration Agreement, including the recitals and the attached Schedules, asmay be amended from time to time by the Parties in accordance with its terms ; 1.3 shall mean any applicable law, rule, regulation, or other legally binding measure of anyjurisdiction that relates to bribery or corruption ; 1.4 has the meaning set forth on Schedule 6 ; 1.5 means the IP and other rights in the DNDi Background Technology or the EntasisBackground Technology respectively that were either : ( i ) Controlled by the relevant Party as of the EffectiveDate ; or ( ii ) conceived and reduced to practice, made or developed and Controlled by a Party during the Termoutside the scope of the Collaboration Programme ; 1.6 means the occurrence of a tender offer, stock purchase, other stock acquisition, merger, consolidation, recapitalisation, reverse split, sale or transfer of assets or other transaction, as a resultof which any natural or legal person gains control of an entity or a group ; 1.7 shall mean any clinical study on the Drug Product where the Drug Product is administered tohumans ; 1.8 shall mean have the meaning set out in the recitals ; 1.9 shall mean the collaboration programme to : ( i ) develop a Drug Product in theField and to register such Drug Product in the Field in the DNDi Territory and the Entasis Territory inaccordance with the Development Plan and the Regulatory Plan ; and ( ii ) organise the Manufacture of suchDrug Product for Commercialisation in the Field in the DNDi Territory and the Entasis Territory in accordancewith the Manufacturing and Supply Plan ; 1.10 shall mean any IP and other rights in the API, the Drug Product and theRegulatory Dossier developed or conceived and reduced to practice in the performance of the CollaborationProgramme ; 2 | Page [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filedseparately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, asamended